MarginBio is a leading startup specializing in advanced antibody display technology, aimed at identifying protein biologics capable of targeting the most complex and emerging drug targets effectively.

Engineered with precision, our unique discovery platform capitalizes on target antigens in their native biomedical states and cellular environments, striving for unparalleled innovation in drug target pharmacology and tissue specificity.

Our strategy prioritizes campaigns targeting multispan membrane proteins directly on whole cells, bypassing the complexities of antigen purification, to streamline the path from discovery to development.